Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer

Liver Cancer Clinical Trial

Official title:

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06251115
• Other study ID #: IIT-QY-1-T
• Status: Recruiting
• Phase: N/A
• Start date: January 26, 2024
• Est. completion date: October 30, 2025

Study information

• Verified date: April 2024
• Source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Jiang Long, MD
• Phone: +86 18017317460
• Email: jiang.long[@]shgh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The vast majority of liver cancers have an insidious onset and are often asymptomatic in the early stages, making early diagnosis difficult. Once diagnosed, most liver cancers have reached locally advanced stages or distant metastases, equivalent to Barcelona stage (BCLC) C-D. The tumors progress rapidly and there is a lack of effective treatments. The survival period of cancer patients is generally only 3-6 months. Cellular immunotherapy, including CAR-T and TCR-T, is considered a new hope for the treatment of cancer.

The purpose of this study is to explore the safety of QY-1-T (a TCR-T targeting HBV) in the treatment of HBV-related liver cancer, and to preliminarily evaluate the efficacy of QY-1-T in patients with HBV-related advanced liver cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: October 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects aged 18-75 years old (male or female)

2. The subject voluntarily participate and have the ability to sign the informed consent independently

3. Patient with advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology (BCLC stage B and C, or CNLC stage IIA/IIB and IIIA/IIIB). One of the following four conditions applies:a. Patients with advanced hepatocellular carcinoma (HCC) who are not candidates for surgery or local therapy and have previously failed or become intolerable after at least second-line or higher standardized systemic therapy (including but not limited to targeted therapy, immunotherapy, or chemotherapy) and whose disease progression or intolerance has been determined by imaging examination during or after treatment, Or patients whom the investigator believes could benefit. b. HCC patients with clinically confirmed recurrence or progression after local treatment, and the interval between treatment and enrollment is at least 4 weeks. c. HCC recurrence after resection progresses or is not tolerated by systemic therapy or TACE/HAIC or radiofrequency ablation, and the interval between treatment and entrainment is at least 4 weeks. d. Recurrence of liver cancer after liver transplantation progresses or is not tolerated after systemic therapy or TACE/HAIC or radiofrequency ablation, and the interval between treatment and entrainment is at least 4 weeks

4. Prior systemic therapy should be discontinued for at least 2 weeks prior to enrollment

5. The expected survival time is more than 6 months

6. The subject has at least one tumor lesion that can be measured according to RECIST1.1

7. Hepatitis B virus surface antigen (HBsAg) positive or previous positive history

8. The HLA typing of peripheral blood was HLA-A*11:01

9. Non-cirrhosis or compensatory cirrhosis Child-Pugh < 7 score

10. ECOG scoring standard =1

11. Blood routine and blood biochemical indicators: a. white blood cells =3×10^9/L. b. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =5× upper limit of normal (ULN). c. Serum total bilirubin =2×ULN. d.eGFR=60ml /min. e. Hemoglobin > 90g/L. f. Platelet count =50×10^9/L. g. Creatinine =1.5×ULN. h. International standardized ratio INR=1.5 or activated partial thrombin time (APTT) extended within 10s.

12. Female subjects of childbearing age, whose serum pregnancy tests must be negative, and all subjects must agree to take effective contraceptive measures during the test

13. Subject agrees to abstain from alcohol during the study

14. The subject is willing and able to follow all treatment procedures and protocols

Exclusion Criteria:

1. The presence of a secondary primary malignancy, except in the following cases: a. Non-melanoma treated by excision, such as basal cell skin cancer. b. curable carcinoma in situ, such as cervical, bladder or breast cancer

2. Liver tumor load exceeds 70%

3. Co-transplanters

4. Main portal vein cancer thrombus

5. Moderate to severe ascites

6. Human immunodeficiency virus (HIV) 1 or 2 positive or acquired immunodeficiency syndrome (AIDS) history, treponema pallidum antibody positive

7. Decompensated cirrhosis Child-Pugh B or C (7-15 points)

8. Clinically significant bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, hereditary or acquired bleeding and thrombosis tendency (such as hemophilia, coagulation disorder, thrombocytopenia, hypersplenism, etc.) within 2 weeks prior to the study, and more serious arteriovenous thrombosis events occurring within the previous 6 months,Such as cerebrovascular diseases (including cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.

9. Have high blood pressure that cannot be effectively controlled, i.e. systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg after antihypertensive treatment

10. Serum HBV DNA=1000 IU/ml during screening (HBV positive for transplant donors of primary liver cancer patients), antiviral treatment can be performed according to the actual situation before admission

11. HCV RNA positive

12. Prior cell therapy, such as but not limited to NK, CIK, DC, CTL, stem cell therapy

13. Concurrent treatment with other anti-tumor therapies, including cytotoxic chemotherapy, hormone therapy and immunotherapy

14. Use of immune checkpoint inhibitors within 1 month

15. Patient with Grade III or IV cardiac dysfunction, arrhythmias that cannot be controlled by drugs or QTc interval > 450ms for men and > 470ms for women according to the NYHA grading criteria

16. Any other medical conditions that may increase subjects' risk or interfere with study results

17. Has any condition that interferes with drug administration and study sample collection

18. Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders

19. Participate in other drug clinical studies within 4 weeks before screening

20. Pregnant or lactating women

21. Failure to follow or cooperate with relevant treatment procedures and protocols during the study period

Related Conditions & MeSH terms

• Liver Cancer
• Liver Neoplasms

Intervention

Drug:
• QY-1-T
QY-1-T is a TCR-T drug targeting HBV-related HCC

Locations

Country	Name	City	State
China	Shanghai General Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Efficacy: antiviral activity of QY-1-T	Changes in serum levels of hepatitis B surface antigen (HBsAg) before and after QY-1-T infusion	Up to 1 year after the last infusion
Other	Efficacy: antiviral activity of QY-1-T	Changes in serum levels of hepatitis B virus deoxyribonucleic acid (HBV-DNA) before and after QY-1-T infusion	Up to 1 year after the last infusion
Primary	Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT)	To assess the tolerability of QY-1-T and determine the maximum tolerated dose (MTD)	Up to 1 month after the last infusion
Secondary	Efficacy: antitumor activity of QY-1-T in subjects with HBV-related HCC	Tumor response assessment in accordance with mRECIST and iRECIST	Up to 1 year after the last infusion